Stonepine Capital Management’s Alimera Sciences ALIM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-3,511,816
| Closed | -$19.5M | – | 41 |
|
|
2024
Q2 | $19.5M | Sell |
3,511,816
-539,256
| -13% | -$1.92M | 17.81% | 2 |
|
|
2024
Q1 | $15.8M | Buy |
4,051,072
+51,613
| +1% | +$196K | 12.53% | 3 |
|
|
2023
Q4 | $17.3M | Buy |
3,999,459
+15,773
| +0.4% | +$53.3K | 7.47% | 5 |
|
|
2023
Q3 | $12.3M | Buy |
+3,983,686
| New | +$13.2M | 4.1% | 6 |
|
|
2019
Q4 | – | Sell |
-182,694
| Closed | -$1.55M | – | 30 |
|
|
2019
Q3 | $1.55M | Sell |
182,694
-246,606
| -57% | -$2.24M | 1.51% | 17 |
|
|
2019
Q2 | $5.73M | Sell |
429,300
-2,941
| -0.7% | -$41.4K | 3.95% | 8 |
|
|
2019
Q1 | $6.87M | Sell |
432,241
-4,277
| -1% | -$65.1K | 3.95% | 10 |
|
|
2018
Q4 | $4.7M | Sell |
436,518
-29,339
| -6% | -$428K | 4.13% | 11 |
|
|
2018
Q3 | $6.85M | Buy |
465,857
+445
| +0.1% | +$6.77K | 4% | 10 |
|
|
2018
Q2 | $6.83M | Buy |
465,412
+53,410
| +13% | +$751K | 4.15% | 9 |
|
|
2018
Q1 | $6.37M | Buy |
412,002
+174,675
| +74% | +$3.1M | 3.41% | 11 |
|
|
2017
Q4 | $4.74M | Buy |
237,327
+205,512
| +646% | +$4.01M | 2.84% | 15 |
|
|
2017
Q3 | $644K | Buy |
31,815
+19,493
| +158% | +$417K | 0.38% | 21 |
|
|
2017
Q2 | $257K | Sell |
12,322
-159,430
| -93% | -$3.42M | 0.14% | 25 |
|
|
2017
Q1 | $3.61M | Sell |
171,752
-135,969
| -44% | -$2.62M | 2.03% | 15 |
|
|
2016
Q4 | $4.99M | Buy |
307,721
+180,575
| +142% | +$3.31M | 2.97% | 12 |
|
|
2016
Q3 | $2.84M | Buy |
+127,146
| New | +$2.93M | 2.32% | 10 |
|
Stonepine Capital Management's ALIM Position: Q3 2024 in Review
Stonepine Capital Management sold out of Alimera Sciences (ALIM) in Q3 2024, closing a stake of 3,511,816 shares — an estimated $19.5M sold.
Stonepine Capital Management first reported a position in ALIM in Q3 2016 and held it in 17 quarters. The position peaked at $19.5M in Q2 2024. 0 funds tracked by Wall St. Rank hold ALIM as of Q3 2024.
- Stonepine Capital Management reported no remaining Alimera Sciences position as of Q3 2024 after selling out during the quarter.
- Stonepine Capital Management sold 3,511,816 Alimera Sciences shares in Q3 2024, an estimated $19.5M.
- Stonepine Capital Management first reported a position in Alimera Sciences in Q3 2016 and held it in 17 quarters.
- Stonepine Capital Management's Alimera Sciences position peaked at $19.5M in Q2 2024.
- 0 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2024.
Based on Stonepine Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.